Skip to content

Evaluation of efficacy of local injection of mesenchymal stem cells for the treatment of neuropathic diabetic foot ulcer

Evaluation of efficacy of local injection of menstrual blood-derived mesenchymal stem cells SinaBioMBcell for the treatment of chronic neuropathic diabetic foot ulcer in a phase III double-blind randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180619040147N5
Enrollment
80
Registered
2021-03-29
Start date
2021-04-14
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Treatment of chronic neuropathic diabetic foot ulcers. Condition 2: Treatment of chronic neuropathic diabetic foot ulcers. Condition 3: Treatment of chronic neuropathic diabetic foot ulcers. Type 2 diabetes mellitus with foot ulcer Type 1 diabetes mellitus with foot ulcer Type 2 diabetes mellitus with diabetic neuropathy, unspecified

Interventions

Intervention 1: 40 volunteer patients who refer to the Wound and Tissue Repair Research Center of the University of Medical Sciences, Academic Center for Education, Culture, and Research, will be exam

Sponsors

Iranian academic center for education culture and research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Chronic diabetic ulcers (more than 6 weeks) grade I-II Wagner classification without osteomyelitis Full thickness ulcer The size of the wound has to be between1-8 cm2 Controlled blood sugar (HbA1c less than 10) Patient's consent and clarification on whether they may be concluded in control or treatment group Non responsive ulcers to previous medications and treatments

Exclusion criteria

Exclusion criteria: Ulcers that are classified as grade 3-4 of Wagner classification or osteomyelitis has occurred Patients that don't meet the age criteria of the study High blood sugar levels The wounds that do not include full layers of skin. The wounds healed by other standard diabetic ulcers treatment methods

Design outcomes

Primary

MeasureTime frame
Full thickness closure progress. Timepoint: Before treatment, the first, second, fourth, fifth, and sixth weeks and again on third, fourth, fifth, and sixth-months post-treatment. Method of measurement: On each evaluation period, the wounds will be measured with special devices like a ruler specialized for wound measurements.

Secondary

MeasureTime frame
Evaluation of local side effects (irritation, inflammation, pain, granulation, infection). Timepoint: Before treatment, the first 48 hours, and again from the first week till week six of the study. Method of measurement: Clinical observation.;Evaluation of systematic side effects (skin sensitivity, fever, shivering, nausea, vomiting). Timepoint: Before treatment, the first 48 hours, and again from the first week till week six of the study. Method of measurement: Clinical observation.;The rate of wound healing. Timepoint: Before treatment, then from first week till week six and then every month till six months post treatment. Method of measurement: Clinical observation.;Duration of complete wound healing. Timepoint: From week one, till week six, and then every month till six months post-treatment. Method of measurement: Clinical observation.;Side effects of choronic diabetic wounds on patients ( the need of antibiotics prescription and Hospitalization). Timepoint: From week one, till week six, and then every month till six months post-treatment. Method of measurement: Clinical observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Esmaeil Javid

Iranian academic center for education culture and research

djavid@ut.ac.ir+98 21 6698 9110

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026